Cardiovascular risk and inflammatory rheumatic diseases

Alhusain, Awal; Bruce, Ian N.

doi:10.7861/clinmedicine.13-4-395

Cited by 15 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ROC curve analysis estimated 16.26 m/s as optimal cut-off value of ba-PWV for CVE (area under the curve: 0.672, 95% CI: 0.594–0.750, p < 0.001; sensitivity and specificity were 45.9 and 83.7%, respectively). Increased ba-PWV was independently associated with CVEs in patients with TAK, therefore according to this study higher ba-PWV may be a potential marker to predict CVE in TAK ( 59 ).…”

Section: Resultsmentioning

confidence: 59%

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Chronic inflammation represents the cornerstone of the raised cardiovascular (CV) risk in patients with inflammatory rheumatic diseases (IRD), including vasculitis. Standardized mortality ratios in these patients are higher as compared to the general population, and the excess of premature mortality is due to early atherosclerotic events. Thus, IRD patients need appropriate CV risk assessment and management according to this CV disease (CVD) burden. Adequate control of CV risk is still lacking in usual care, but early diagnosis of silent and subclinical CVD is crucial to improve the long-term prognosis of these patients. Increased arterial stiffness may provide a pathophysiological link between inflammation and increased cardiovascular risk. Several noninvasive methods are now available to estimate artery stiffness in the clinical setting, including pulse wave velocity assessment. The independent predictive value of arterial stiffness for cardiovascular events has been demonstrated in general as well as in selected populations, and reference values adjusted for age and blood pressure have been suggested. Thus, arterial stiffness is an interesting biomarker for cardiovascular risk stratification. This systematic review summarizes the additional value that PWV measurement can provide in the setting of vasculitis, with a focus in the different clinical stages and CV risk prevention. This systematic review is registered with registration number: Prospero CRD42021259603.

show abstract

Section: Resultsmentioning

confidence: 59%

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The proposed management of cardiovascular disease in SLE patients aims for an ideal blood pressure of <130/80, an ideal LDL level <100 mg/dl, and an ideal BMI<25 kg/m 2 . Patients are encouraged to use anti-malarial drugs, undergo smoking cessation, and to minimize or even withdraw from steroids, with a goal of stricter control of inflammation [49].…”

Section: Atherosclerosis and Slementioning

confidence: 99%

Atherosclerosis and Rheumatic Diseases

Mattar¹,

Bochra²,

Ali

et al. 2015

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

Until recently, patients with chronic autoimmune diseases were dying at a young age from their disease. However, with the emergence of biologic drugs and disease-targeted therapies, longevity in this patient population has increased. In addition, physicians have become more aware of the long-term sequelae of chronic inflammation focusing mainly on the development of premature atherosclerosis. In this review we will systematically analyze the most relevant published papers for the PubMed Central database and other validated-internet sources that have relevance to the role that atherosclerosis plays in several autoimmune diseases including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). We also examined the effects of disease modifying agents on the development of atherosclerosis in patients with autoimmune diseases as well as identifying strategies or interventions which can prevent or retard the development of cardiovascular disease in these patients.

show abstract

“…Patients with rheumatoid arthritis and other connective tissue diseases are known to be at increased risk for CAD. 65,66 Both increased prevalence of traditional risk factors and nontraditional risk factors related to chronic systemic inflammation are thought to contribute to this increased risk. The European Society of Cardiology/European Atherosclerosis Society Guidelines recognize the increased risk of ASCVD in these patients but discourage the preventive use of lipid-lowering drugs on the basis of the presence of autoimmune diseases.…”

Section: Lipid Management In Patients With Rheumatologic Inflammatory Diseasementioning

confidence: 99%

A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps

López-Jiménez

Simha

Thomas

et al. 2014

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Practice Guidelines has recently released the new cholesterol treatment guideline. This update was based on a systematic review of the evidence and replaces the previous guidelines from 2002 that were widely accepted and implemented in clinical practice. The new cholesterol treatment guideline emphasizes matching the intensity of statin treatment to the level of atherosclerotic cardiovascular disease (ASCVD) risk and replaces the old paradigm of pursuing low-density lipoprotein cholesterol targets. The new guideline also emphasizes the primacy of the evidence base for statin therapy for ASCVD risk reduction and lists several patient groups that will not benefit from statin treatment despite their high cardiovascular risk, such as those with heart failure (New York Heart Association class II-IV) and patients undergoing hemodialysis. The guideline has been received with mixed reviews and significant controversy. Because of the evidence-based nature of the guideline, there is room for several questions and uncertainties on when and how to use lipid-lowering therapy in clinical practice. The goal of the Mayo Clinic Task Force in the assessment, interpretation, and expansion of the ACC/AHA cholesterol treatment guideline is to address gaps in information and some of the controversial aspects of the newly released cholesterol management guideline using additional sources of evidence and expert opinion as needed to guide clinicians on key aspects of ASCVD risk reduction.

show abstract

Cardiovascular risk and inflammatory rheumatic diseases

Cited by 15 publications

References 20 publications

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review

Atherosclerosis and Rheumatic Diseases

A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps

Contact Info

Product

Resources

About